Molecure to begin clinical development of novel dual arginase inhibitor OATD-02 for the treatment of cancer after gaining permission to conduct first clinical trial in Poland
/PRNewswire/ -- Molecure S.A. ("Molecure") (WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and...
Molecure Third Quarter 2022 Pipeline Highlights and Financial Results
/PRNewswire/ -- Molecure S.A. ("Molecure") (WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and...